Catalog No: CFN99563

Coptisine is an efficient uncompetitive IDO inhibitor with a Ki value of 5.8 μM and an IC50 value of 6.3 μM, it can consequently prevent neuron loss, reduce amyloid plaque formation, and ameliorate impaired cognition, it could as a potential new class of drugs for AD treatment. Coptisine has cardioprotection, anti- hypercholesterolemia, anti-fungal, anti-osteosarcoma, anti-hepatoma and anti-leukaemia activities, it also has antispasmodic and relaxant activity on a guinea-pig ileum.
Catalog No: CFN99710

Wogonoside has anticoagulant, anti-inflammatory, anti-angiogenic and anticancer effects, it may exert its anti-inflammatory effect via dual inhibition of NF-κB and NLRP3 inflammasome. Wogonoside induced autophagy through the MAPK-mTOR pathway, it inhibited LTB 4 production at the concentration of 100 uM.
Palmitic acid
Catalog No: CFN99716

Palmitic acid induces anxiety-like behavior in mice while increasing amygdala-based serotonin metabolism, it induces down-regulation of APOM expression, is mediated via the PPARβ/δ pathway. Palmitic acid induces degeneration of myofibrils and modulate apoptosis in rat adult cardiomyocytes. it also shows in vivo antitumor activity in mice. Palmitic acid is CNS mediated via PKC-theta activation, resulting in reduced insulin activity.
Catalog No: CFN99735

(S)-10-Hydroxycamptothecin is a DNA topoisomerase I inhibitor, it is a clinical therapy agent against hepatoma.
Catalog No: CFN99947

Bufalin a major digoxin-like immunoreactive component of the Chinese medicine Chan Su; has been shown to exert a potential for anticancer activity against various human cancer cell lines in vitro. Bufalin is a potent small-molecule inhibitor of the steroid receptor coactivators steroid receptor coactivator (SRC)-3 and SRC-1, it also as a potentially broad-spectrum small-molecule inhibitor for cancer. Bufalin can partly reverse the MDR of K562/VCR cells, with a possible mechanism of down-regulating MRP1 expression and activating apoptosis pathway by altering Bcl-xL/Bax ratio.